journal
https://read.qxmd.com/read/37741790/validation-of-the-2023-figo-staging-schema-for-advanced-endometrial-cancer
#1
LETTER
Koji Matsuo, Maximilian Klar, Bonnie B Song, Lynda D Roman, Jason D Wright
No abstract text is available yet for this article.
September 21, 2023: European Journal of Cancer
https://read.qxmd.com/read/37678104/response-to-response-to-letter-entitled-re-toxicities-associated-with-chemotherapy-regimens-containing-a-fluoropyrimidine-a-real-life-evaluation-in-france
#2
LETTER
Bernard Guennebaud, Alain Rivoire
No abstract text is available yet for this article.
September 5, 2023: European Journal of Cancer
https://read.qxmd.com/read/37741071/a-phase-ii-study-on-the-efficacy-of-regorafenib-in-treating-patients-with-c-kit-mutated-metastatic-malignant-melanoma-that-progressed-after-previous-treatment-kcsg-un-14-13
#3
JOURNAL ARTICLE
Kyoo Hyun Kim, Minkyu Jung, Hyo Jin Lee, Su Jin Lee, Miso Kim, Mi Sun Ahn, Moon Young Choi, Na-Ri Lee, Sang Joon Shin
BACKGROUND: c-KIT mutations are found in approximately 15% of patients with malignant melanoma in the Asian population. Regorafenib, an oral multikinase inhibitor, acts against both wild-type and mutant KIT. OBJECTIVE: This multi-institutional, phase II, single-arm study aimed to evaluate the efficacy of regorafenib against metastatic malignant melanoma harbouring c-KIT mutations. METHODS: Patients with metastatic melanoma positive for c-KIT mutations, upon progression after at least one line of systemic treatment, were enroled...
August 28, 2023: European Journal of Cancer
https://read.qxmd.com/read/37722270/upfront-liquid-next-generation-sequencing-in-treatment-na%C3%A3-ve-advanced-non-small-cell-lung-cancer-patients-a-prospective-randomised-study-in-the-taiwanese-health-system
#4
JOURNAL ARTICLE
Ching-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, Chao-Chi Ho, Chia-Lin Hsu, Tzu-Hsiu Tsai, Shang-Gin Wu, Yen-Ting Lin, Wei-Hsun Hsu, Suyog Jain, Steve Olsen, James Chih-Hsin Yang, Chong-Jen Yu, Pan-Chyr Yang
BACKGROUND: Next-generation sequencing (NGS) of plasma cell-free DNA identifies driver mutations in advanced non-small cell lung cancer (NSCLC) and may complement routine molecular evaluation. The utility of liquid NGS at the start of tumour workup is undetermined. METHODS: This is a randomised study of patients with suspected advanced NSCLC. All patients received blood liquid NGS testing at their first clinic visit and underwent standard histological diagnosis and tissue genotyping, encompassing polymerase chain reaction based methods for EGFR mutation, immunohistochemical (IHC) staining for ALK fusion and BRAF V600E mutation, and an IHC screening followed by confirmation using fluorescence in situ hybridization confirmation for ROS1 fusion...
August 28, 2023: European Journal of Cancer
https://read.qxmd.com/read/37648571/letter-re-sequential-therapies-after-atezolizumab-plus-bevacizumab-or-lenvatinib-first-line-treatments-in-hepatocellular-carcinoma-patients
#5
LETTER
Qian Ding, Ming-Cheng Guan, Hong Zhu
No abstract text is available yet for this article.
August 28, 2023: European Journal of Cancer
https://read.qxmd.com/read/37729742/diagnostic-accuracy-of-ct-for-local-staging-of-colon-cancer-a-nationwide-study-in-the-netherlands
#6
JOURNAL ARTICLE
Jona Shkurti, Kim van den Berg, Felice N van Erning, Max J Lahaye, Regina G H Beets-Tan, Joost Nederend
OBJECTIVE: To determine the accuracy of computed tomography (CT)-based staging in selecting high-risk colon cancer patients who would benefit from neoadjuvant chemotherapy while avoiding overtreatment. METHODS: Data of adult patients diagnosed with non-metastatic primary colon cancer in 2005-2020, who underwent surgical resection without neoadjuvant chemotherapy, were retrospectively collected from the Netherlands Cancer Registry. Agreement between clinical and pathological evaluation for each T and N stage was calculated...
August 25, 2023: European Journal of Cancer
https://read.qxmd.com/read/37717281/phase-ii-study-of-trifluridine-tipiracil-in-metastatic-breast-cancers-with-or-without-prior-exposure-to-fluoropyrimidines
#7
JOURNAL ARTICLE
Joline S J Lim, Samuel G W Ow, Andrea L A Wong, Matilda X W Lee, Gloria H J Chan, Jia Li Low, Raghav Sundar, Joan R E Choo, Wan Qin Chong, Yvonne L E Ang, Bee Choo Tai, Soo Chin Lee
BACKGROUND: Fluoropyrimidines are commonly used in the treatment of metastatic breast cancer (MBC), and trifluridine/tipiracil (FTD/TPI) has shown activity in patients with colorectal and gastric cancers despite prior exposure to fluoropyrimidines. We investigate the role of FTD/TPI in patients with MBC with or without prior fluoropyridines in a single-arm phase II study. METHODS: Patients with MBC were enroled first into a run-in dose confirmation phase, followed by two parallel cohorts including patients with (Cohort A) and without (Cohort B) prior exposure to fluoropyrimidines, where they were treated with FTD/TPI...
August 25, 2023: European Journal of Cancer
https://read.qxmd.com/read/37625239/secondary-hypertrophic-osteoarthropathy-revealing-a-metastatic-melanoma
#8
LETTER
J Laillet, P Monnet, L Goldfarb, R Belkhir, C Robert
No abstract text is available yet for this article.
August 23, 2023: European Journal of Cancer
https://read.qxmd.com/read/37620211/response-to-letter-entitled-re-anthropometric-indicators-of-adiposity-and-risk-of-primary-liver-cancer-a-systematic-review-and-dose-response-meta-analysis
#9
LETTER
Lun-Jie Yan, Long-Shan Yang, Tao Li
No abstract text is available yet for this article.
August 22, 2023: European Journal of Cancer
https://read.qxmd.com/read/37620210/response-to-letter-entitled-re-anthropometric-indicators-of-adiposity-and-risk-of-primary-liver-cancer-a-systematic-review-and-dose-response-meta-analysis
#10
LETTER
Gang Zhao, Xiaobao Shi, Lingyun Zhang, Hongyuan Liang
No abstract text is available yet for this article.
August 22, 2023: European Journal of Cancer
https://read.qxmd.com/read/37620209/response-to-letter-entitled-re-sequential-therapies-after-atezolizumab-plus-bevacizumab-or-lenvatinib-first-line-treatments-in-hepatocellular-carcinoma-patients
#11
LETTER
Mara Persano, Margherita Rimini, Andrea Casadei Gardini
No abstract text is available yet for this article.
August 22, 2023: European Journal of Cancer
https://read.qxmd.com/read/37713740/smoking-impairs-the-effect-of-neoadjuvant-folfirinox-on-postresection-survival-in-pancreatic-cancer
#12
JOURNAL ARTICLE
Carl-Stephan Leonhardt, Dietmar Pils, Motaz Qadan, Charlotte Gustorff, Klaus Sahora, Ulla Klaiber, Andrew L Warshaw, Gerald Prager, Cristina R Ferrone, Keith D Lillemoe, Martin Schindl, Oliver Strobel, Carlos Fernández-Del Castillo, Thomas Hank
INTRODUCTION: Smoking plays an important role in carcinogenesis, including pancreatic ductal adenocarcinoma (PDAC). However, little is known about the association between smoking status and prognosis in resected PDAC. METHODS: All patients who underwent resection for PDAC were identified from two prospective institutional databases. Clinicopathologic data as well as demographics including smoking status were extracted. Survival analysis and multivariable Cox regression modelling was performed...
August 21, 2023: European Journal of Cancer
https://read.qxmd.com/read/37708628/computational-intelligence-analysis-of-high-risk-neuroblastoma-patient-health-records-reveals-time-to-maximum-response-as-one-of-the-most-relevant-factors-for-outcome-prediction
#13
JOURNAL ARTICLE
Davide Chicco, Riccardo Haupt, Alberto Garaventa, Paolo Uva, Roberto Luksch, Davide Cangelosi
OBJECTIVE: Seek new candidate prognostic markers for neuroblastoma outcome, relapse or progression. MATERIALS AND METHODS: In this multicentre and retrospective study, Random Forests coupled with recursive feature elimination techniques were applied to electronic records (55 clinical features) of 3034 neuroblastoma patients. To assess model performance and feature importance, dataset was split into a training set (80%) and a test set (20%). RESULTS: In the test set, the mean Matthews correlation coefficient for the Random Forests models was greater than 0...
August 19, 2023: European Journal of Cancer
https://read.qxmd.com/read/37672816/health-care-and-socioeconomic-costs-for-long-term-survivors-after-implementation-of-checkpoint-inhibitors-and-targeted-agents-for-metastatic-melanoma
#14
JOURNAL ARTICLE
Anne Vest Soerensen, Jakob Kjellberg, Rikke Ibsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane
BACKGROUND: Real-life data on health care costs and loss of productivity after implementing new agents for metastatic melanoma are important to supplement model-based economic data. MATERIALS AND METHODS: All patients registered in the Danish Metastatic Melanoma Database (DAMMED) and the National Patient Registry in 2007-2011 were compared to 2012-2016 after the implementation of checkpoint inhibitors and targeted therapy. Health care costs, social transfer income (STI), and loss of productivity were calculated with a 2-step one model generalised linear regression (GLM) model...
August 19, 2023: European Journal of Cancer
https://read.qxmd.com/read/37717282/efficacy-and-safety-of-cabozantinib-rechallenge-in-metastatic-renal-cell-carcinoma-a-retrospective-multicentric-study
#15
JOURNAL ARTICLE
Edwige Baudry, Natacha Naoun, Edouard Auclin, Carolina Saldana, Philippe Barthelemy, Lionnel Geoffrois, Constance Thibault, Manon de Vries-Brilland, Delphine Borchiellini, Denis Maillet, Laure Hirsch, Charles Vauchier, Lucia Carril-Ajuria, Emeline Colomba, Alice Bernard-Tessier, Bernard Escudier, Ronan Flippot, Laurence Albigès
BACKGROUND: Despite metastatic renal cell carcinoma (mRCC) expanded treatment options, disease progression ultimately occurs for most patients. Rechallenge may be a compelling strategy in a refractory setting. Cabozantinib is the standard of care in first and later lines of therapy, but its activity in rechallenge is unknown. METHODS: This retrospective study assessed the efficacy and safety of cabozantinib rechallenge, as defined by a second exposure after an interval of ≥3 months without treatment or ≥1 other treatment line, in patients with mRCC...
August 18, 2023: European Journal of Cancer
https://read.qxmd.com/read/37690178/a-3-dimensional-histology-computer-model-of-malignant-melanoma-and-its-implications-for-digital-pathology
#16
JOURNAL ARTICLE
Alexander Kurz, Dieter Krahl, Heinz Kutzner, Raymond Barnhill, Antonio Perasole, Maria Teresa Fernandez Figueras, Gerardo Ferrara, Stephan A Braun, Hans Starz, Mar Llamas-Velasco, Jochen Sven Utikal, Stefan Fröhling, Christof von Kalle, Jakob Nikolas Kather, Lucas Schneider, Titus J Brinker
BACKGROUND: Historically, cancer diagnoses have been made by pathologists using two-dimensional histological slides. However, with the advent of digital pathology and artificial intelligence, slides are being digitised, providing new opportunities to integrate their information. Since nature is 3-dimensional (3D), it seems intuitive to digitally reassemble the 3D structure for diagnosis. OBJECTIVE: To develop the first human-3D-melanoma-histology-model with full data and code availability...
August 18, 2023: European Journal of Cancer
https://read.qxmd.com/read/37595488/delayed-and-persistent-multisystem-toxicities-of-adjuvant-anti-pd-1-therapy-for-stage-iii-melanoma
#17
LETTER
Rachel S Goodman, Joy Justice, Laura J Gardner, Reena Singh, Anna K Dewan, Douglas B Johnson
No abstract text is available yet for this article.
August 16, 2023: European Journal of Cancer
https://read.qxmd.com/read/37708629/apalutamide-plus-androgen-deprivation-therapy-in-clinical-subgroups-of-patients-with-metastatic-castration-sensitive-prostate-cancer-a-subgroup-analysis-of-the-randomised-clinical-titan-study
#18
JOURNAL ARTICLE
Axel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, Florence Lefresne, Laurence I Karsh, Andrea J Pereira de Santana Gomes, Álvaro Juárez Soto, Robert W Given, Sabine D Brookman-May, Suneel D Mundle, Sharon A McCarthy, Hirotsugu Uemura, Simon Chowdhury, Kim N Chi, Anders Bjartell
BACKGROUND: Whether disease burden in patients with metastatic castration-sensitive prostate cancer (mCSPC) predicts treatment outcomes is unknown. We assessed apalutamide treatment effect in TITAN patients with mCSPC by disease volume, metastasis number and timing of metastasis presentation. METHODS: These protocol-defined and post hoc analyses of the phase III randomised TITAN study evaluated clinical outcomes in patients receiving 240 mg/day apalutamide (n = 525) or placebo (n = 527) plus androgen-deprivation therapy (ADT)...
August 11, 2023: European Journal of Cancer
https://read.qxmd.com/read/37690179/hyperprogression-in-advanced-melanoma-is-not-restricted-to-immunotherapy
#19
JOURNAL ARTICLE
Marie Fournier, Laurent Mortier, Olivier Dereure, Sophie Dalac, Bastien Oriano, Stéphane Dalle, Céleste Lebbé
BACKGROUND: The definition of hyperprogressive disease (HPD) is controversial in the literature and has not been widely described in melanoma. The aim of this study was to determine whether the concept of HPD applies to patients treated for advanced melanoma, using a definition with a simple, reproducible criterion, and to determine whether it is possible to identify predictive factors for HPD. METHODS: This was a retrospective analysis on a prospective cohort. The data were extracted from MelBase, a French prospective, multicentre cohort of adult patients with advanced melanoma...
August 11, 2023: European Journal of Cancer
https://read.qxmd.com/read/37573219/response-to-letter-entitled-re-association-between-endocrine-therapy-and-cognitive-decline-in-older-women-with-early-breast-cancer-findings-from-the-prospective-climb-study
#20
LETTER
Joosje C Baltussen, Annelieke A Lemij, Nienke A de Glas, Johanneke E A Portielje, Gerrit-Jan Liefers
No abstract text is available yet for this article.
August 10, 2023: European Journal of Cancer
journal
journal
30413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.